Filamin A-interacting protein 1-like C-terminal truncation mutant (1-790) (FILIP1LΔC103) (FILIP1LΔC103)

Filamin A-interacting protein 1-like (FILIP1L), also known as Downregulated in Ovarian Cancer 1 (DOC-1), is a protein that acts as a potent tumor suppressor and is frequently lost or downregulated in various malignancies, including ovarian, colorectal, and prostate cancers [1.1.1, 1.3.1]. The specific variant FILIP1LΔC103 is a C-terminal truncation mutant (comprising amino acids 1-790) that exhibits enhanced anti-proliferative and anti-angiogenic potency compared to the wild-type protein [1.1.2, 1.3.5]. Biologically, FILIP1L functions by inhibiting the canonical WNT/beta-catenin signaling pathway, promoting the degradation of beta-catenin at the centrosome, and subsequently suppressing the epithelial-to-mesenchymal transition (EMT) [1.3.2, 1.3.3]. This suppression leads to reduced tumor cell migration, invasion, and increased apoptosis, making it a significant target for gene therapy interventions [1.1.2, 1.3.1]. In clinical contexts, low FILIP1L expression serves as a biomarker for poor prognosis, advanced disease stage, and resistance to chemotherapeutic agents like cisplatin [1.3.2, 1.3.3]. Experimental therapies have utilized nanogel-mediated delivery of FILIP1LΔC103 to inhibit tumor growth and sensitize cancer cells to standard chemotherapy [1.1.2, 1.3.5].

Other names

DOC-1Downregulated in Ovarian Cancer 1GIP130GIP90130 kDa GPBP-interacting proteinFilamin A-interacting protein 1-like

Restoration of tumor suppressor function through inhibition of the WNT/beta-catenin pathway and suppression of epithelial-to-mesenchymal transition (EMT).